Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 12, 2025Annals of HematologyOpen Access

Infection events in patients with newly diagnosed multiple myeloma with anti-CD38 monoclonal antibody-based first line regimens: A multicentric Italian experience

View Full Paper
Ask AI
Bookmark
Share

Authors

ARAngela RagoFFFrancesca FioritoniCLCarmine Liberatore

Discussion

Loading...

Member takes

Overview

Retrospective analysis highlights infection incidence in patients with multiple myeloma, indicating risks associated with therapies.

Key Points

  • Infections affected 31.3% of newly diagnosed multiple myeloma patients undergoing therapy.
  • Treatment regimens did not show significant differences in infection rates across subgroups, ensuring stable outcomes.
  • Retrospective analysis conducted on 472 patients across 10 treatment centers in Italy from 2020 to 2023.
  • Findings suggest the need for further research to identify infection risk factors in multiple myeloma treatment.

Cite This Study

Rago et al. (2025) studied this question.

synapsesocial.com/papers/68ec1be02b8fa9b2b78ad333https://doi.org/10.1007/s00277-025-06645-y
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Daratumumab-based therapy for newly diagnosed multiple myeloma patients with renal impairment：a multicenter retrospective study from China2025
  2. 2A clinical overview of infection in patients receiving elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) for newly diagnosed multiple myeloma in the MagnetisMM-6 trial2025
  3. 3Incidence and risk factors for infections in the real-world setting in newly diagnosed myeloma patients treated with modern induction regimens2025
  4. 4Use of CD38 antibodies in high-risk newly diagnosed multiple myeloma – meta-analysis2025
  5. 5Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results2025